Study of TTX-MC138 in Subjects With Advanced Solid Tumors
brief summary
A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in Subjects with Advanced Solid Tumors
detailed description
The study will consist of 2 phases, dose escalation and dose expansion, with 3 study periods: Screening (up to 28 days), Treatment (28-day treatment cycles, with dosing on Day 1), and Survival Follow-up (every 3 months). Each 28-day cycle is comprised of 1 dose of study drug administered as an intravenous (IV) infusion on Day 1.
A subject will continue on treatment until a dose limiting toxicity (DLT) is observed, other adverse event (AE) leading to unacceptable toxicity as assessed by the Investigator, progression of disease, or withdrawal of consent.
official title
A Phase 1/2 Multicenter, Open-Label, Dose-escalation and Expansion Study of TTX-MC138 in Subjects With Advanced Solid Tumors